Aditxt

Aditxt does not publicly detail a sourcing pipeline. Its website describes a model of acquiring disruptive, innovative, and scalable companies in targeted markets. The firm likely identifies candidates through its stated network of research institutions and industry partners, but no specific criteria or past deal origination strategies are disclosed.

Aditxt operates as a publicly traded holding company that acquires majority or full ownership of health-focused subsidiaries. It is not a traditional venture capital fund. The firm uses its internal business acceleration platform to grow these companies, then seeks to monetize them through public offerings, sales, or spin-offs.

Evofem is listed as a planned or proposed acquisition on Aditxt's website as of the latest available snapshot. Evofem focuses on reproductive health. No further details about deal status, regulatory approvals, or financial terms are publicly provided by Aditxt.

Aditxt's website does not name any executives, board members, or investment committee members. The firm's public filings with the SEC would contain the names of directors and officers, but information about an investment committee or specific decision-making authority is not available from its corporate website.

Aditxt is a publicly traded company, trading under its own ticker, and thus raises capital from public equity markets. It does not describe a model of managing external fund commitments or limited partner capital for a discrete investment vehicle.